Natera Inc.

NTRA

Held by 3 specialist biotech funds

High Convergence

Share on X

Fund Holdings

3 fund convergence

Driehaus Capital RTW Investments OrbiMed Advisors

Catalysts

No catalysts tracked.

Position Details

Driehaus CapitalNEWFeb 17, 2026

Shares: 625,912Value: $143.4M

# Signal Note: Driehaus Initiates $143M Position in Natera Driehaus's $143M entry into NTRA signals conviction in the company's noninvasive prenatal testing (NIPT) and oncology liquid biopsy franchises, particularly as reproductive health regulation stabilizes post-Dobbs and cell-free DNA adoption accelerates in oncology screening. The timing aligns with NTRA's expanding reimbursement for Signatera (ctDNA-based recurrence monitoring) and upcoming data readouts in early cancer detection, areas where the company faces meaningful competitive pressure from Illumina, Exact Sciences, and Foundation Medicine.

RTW InvestmentsNEW

More NTRA Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

NBIX3 funds ARGX3 funds AXSM3 funds TARS3 funds PTCT3 funds CMPS3 funds JBIO3 funds CRNX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

AI Signal

AI analyst context — unlock full analysis

# Signal Note: RTW Investments Initiates $343.6M Position in Natera (NTRA) RTW's substantial entry suggests conviction in Natera's core non-invasive prenatal testing (NIPT) franchise and expanding oncology liquid biopsy portfolio, particularly Signatera for minimal residual disease (MRD) detection across solid tumors. The timing may reflect anticipated reimbursement decisions or clinical readouts in 2024-2025 that could validate MRD as a standard-of-care biomarker, driving volume and margin expansion beyond current prenatal diagnostics revenues.